AffaMed Therapeutics News and Activities

View the org chart displaying its 10 main executives

Most searched biographies at AffaMed Therapeutics

• Honggang Feng, Chief Executive Officer
• Vijay Karwal, Director
• Lucia Qian, Director

Create your alert
to follow the executive moves at AffaMed Therapeutics.

AffaMed Therapeutics has 2,347 competitors including Incyte (United States (USA)), Anthos Therapeutics (United States (USA)) and Valneva (France).

Popular M&A news in Biotechnology

• The new name of Synaptogenix is TAO Synergies. (posted on July 3 2025).
• AbbVie has announced the acquisition of Capstan Therapeutics  (posted on July 1 2025).
• Neuron23 has just announced a $97 Million fundraising (posted on June 30 2025).

Popular contacts in Biotechnology

• Jasbir Seehra - Chief Executive Officer and Chairman of the Board at Keros Therapeutics
• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Andrea Jackson - Director at Ultivue

Learn more about the Biotechnology industry

Press releases by AffaMed Therapeutics

• AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctiviti
• AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery-Press Releases-AffaMed蔼睦医疗
• AffaMed Technologies Announces Licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL-Press Releases-AffaMed蔼睦医疗
• AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA ® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery-Press Releases-AffaMed蔼睦医疗
• AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib (Luminate®) First-in-Class Candidate for the Treatment of Intermediate Dry AMD-Press Releases-AffaMed蔼睦医疗
• Press Releases-AffaMed蔼睦医疗
• AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder-Press Releases-AffaMed蔼睦医疗
• AffaMed Therapeutics Announces Release of Headache Clinical Decision Support System-Press Releases-AffaMed蔼睦医疗
• AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA ® in Cataract Surgery Patients-Press Releases-AffaMed蔼睦医疗
• AffaMed Therapeutics Announces Partner Allgenesis Reports Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema -Press Releases-AffaMed蔼睦医疗
• View more press releases Close

Social media about AffaMed Therapeutics

• AffaMed Therapeutics on Wikipedia, Google News & Yahoo Finance
• AffaMed Therapeutics on LinkedIn, Twitter & YouTube